<div id="readability-page-1"><div>Milliman Medical Index: Healthcare costs for an American family reach $37,824 in 2026 2026 marks highest healthcare cost increase in more than a decade, as GLP-1 drugs and AI-enabled billing emerge as new drivers Milliman, Inc., the premier global consulting and actuarial firm, today announced the release of the 2026 Milliman Medical Index (MMI), which measures healthcare costs for Americans covered by a typical employer-sponsored health insurance plan. Healthcare costs for the average person rose 7.9% in 2026 to $8,460—the highest annual increase in more than a decade, excluding pandemic-era fluctuations. Healthcare costs for the MMI’s hypothetical family of four reached $37,824. Outpatient facility costs rose 7.5% and pharmacy costs rose 14.8%, with those two service categories accounting for 69% of the total year-over-year increase. &#34;Pharmacy costs have been a persistent driver of healthcare cost growth for several years now, but 2026 represents an acceleration of the trend,&#34; says Milliman Principal and Consulting Actuary Andrew Timcheck. &#34;A 14.8% increase in pharmacy costs—driven by GLP-1 utilization and high-cost specialty drugs—combined with continued outpatient facility cost growth, puts the 2026 trend environment in a category of its own for this decade.&#34; &#34;The 7.9% increase we are seeing this year is not the result of a single acute shock—it reflects structural forces that are not going away,&#34; says Milliman Principal and Consulting Actuary Deana Bell. &#34;Outpatient costs have quadrupled for the MMI’s family of four since the MMI was first published in 2005, with much of the trend exacerbated by delivery system consolidation, specialty drug growth, and site-of-care shifts.” &#34;For the first time in the MMI's history, we're flagging artificial intelligence as a factor in healthcare cost trends,&#34; says Milliman Principal and Consulting Actuary Jason Clarkson. &#34;Hospitals are using AI to optimize their billing and claim coding, and payers are using it to enhance their claim adjudication processes, especially for detecting fraud, waste, and abuse. That dynamic is worth watching as costs hit their highest growth rate in over a decade.&#34; To read the 2026 Milliman Medical Index, visit milliman.com/en/insight/2026-milliman-medical-index. About Milliman Milliman leverages deep expertise, actuarial rigor, and advanced technology to develop solutions for a world at risk. We help clients in the public and private sectors navigate urgent, complex challenges—from extreme weather and market volatility to financial insecurity and rising health costs—so they can meet their business, financial, and social objectives. Our solutions encompass insurance, financial services, healthcare, life sciences, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe. Visit us at milliman.com. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MjAxMTAzNjRyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MjAxMTAzNjRyMQ"/> Jeremy Engdahl-Johnson Milliman, Inc. Tel: +1 646.473.3021 Jeremy.engdahl-johnson@milliman.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260520110364/en/</div></div>

禮來

諾和諾德公司

基因改革 ETF - ARK

2026 年 Milliman 醫療指數顯示，平均美國家庭的醫療費用已達到 37,824 美元，增長了 7.9%，是十多年來的最高水平。主要驅動因素包括藥品費用上漲 14.8%，受 GLP-1 藥物的影響，以及門診設施費用上漲 7.5%。報告強調了人工智能在優化賬單流程中的作用，這對這一顯著的成本增長起到了推動作用

Milliman Medical Index: Healthcare costs for an American family reach $37,824 in 2026

- 2026 年，典型美國家庭醫療成本達 37,824 美元，年增長 7.9%。  
- 藥房費用增長 14.8%，門診費用增長 7.5%，合計佔總增長的 69%。  
- 人工智能首次被標記為醫療成本趨勢因素。

MorningStar

標普醫療保健服務 ETF - SPDR

標普全球醫療股指數 ETF - iShares

2 倍做多 LLY ETF - Defiance

動態生物技術與基因組 ETF - Invesco

2 倍做多 LLY ETF - Direxion

1 倍做空 LLY ETF - Direxion

標普生物技術 3 倍做多 - Direxion

標普生物技術 ETF - SPDR

2 倍做多 NVO ETF - Defiance

紐交所高增長板生物技術指數 ETF - First Trust

醫療業 ETF - SPDR

生物科技 ETF - VanEck Vectors

醫藥突破 ETF - ALPS

標普制藥指數 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

醫療業 ETF - Vanguard

美國制藥 ETF - iShares

Milliman 醫療指數顯示，美國一個家庭的醫療費用將在 2026 年達到 37,824 美元